A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
Scientists around the world agree that we are facing a shortage of effective antibiotics. Innovation is needed now. This is a problem that affects all Americans — and people with cystic fibrosis in particular.
Scientists around the world agree that global innovation is needed to address the shortage of effective antibiotics. Our Infection Research Initiative supports much-needed research and development, but new policies are needed to promote a sustainable, robust antibiotics pipeline and a marketplace that rewards innovation.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).